Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.
A major clinical challenge for treating infectious diseases is the duration of antimicrobial therapy required to eradicate the pathogen. We hypothesized that modulation of the bacterial replication rate in the context of an antimicrobial exposure is coupled with the rate and extent of bactericidal effects. Herein we describe results from in vitro infection model (one compartment, 24-h model; hollow fiber, 10-day model) studies designed to probe the relationship between the bacterial replication rate and the rate and extent of bactericidal effects in the context of an effective antibiotic exposure. The bacterial replication rate was modulated by adjusting the sodium chloride concentration (0 to 8%) in the growth media (Mueller-Hinton II broth). The study drug selected was levofloxacin, and the challenge isolate was Staphylococcus aureus ATCC 29213 (levofloxacin MIC, 0.125 mg/liter). Within each in vitro infection model, human levofloxacin concentration-time profiles (half-life, 7 h) were simulated and the challenge isolate was subjected to an effective exposure (free-drug area under the concentration-time curve over 24 h divided by the MIC [AUC/MIC ratio], 65; administered as a single dose or daily for 10 days). Over the course of each study, samples were taken from each model for bacterial density determinations and drug concentration assay using liquid chromatography-tandem mass spectrometry (LC-MS/MS). In the 24-h one-compartment in vitro infection model studies, as the bacterial replication rate increased, so too did the rate (slope, 0 to 4 h) and extent (24-h CFU count per milliliter) of bacterial killing. In the 10-day hollow-fiber infection model studies, the times until a reduction of bacterial density to 1 × 102CFU/ml occurred were 10 days in the media in which the challenge isolate grew slowly and approximately 2 days in the media in which the challenge isolate grew rapidly. Together, these data provide a proof of concept for new adjunctive therapeutic options with respect to the use of antimicrobial agents alone that reduce treatment durations. Such adjunctive therapies hold promise for marked reductions in the tonnage of antimicrobial agents administered to patient populations and selection pressure toward antimicrobial resistance.
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA PAmbrose@ICPD.com.|University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Paul G
PG
Ambrose
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Brian
B
VanScoy
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Haley
H
Conde
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.
Jennifer
J
McCauley
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.|University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Christopher M
CM
Rubino
Institute for Clinical Pharmacodynamics, Schenectady, New York, USA.|University at Buffalo School of Pharmacy and Pharmaceutical Sciences, Buffalo, New York, USA.
Sujata M
SM
Bhavnani
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002853:Chromatography, Liquid; D064704:Levofloxacin / Q000494:pharmacology*; D008826:Microbial Sensitivity Tests; D009154:Mutation; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000235:genetics; D053719:Tandem Mass Spectrometry
D000890:Anti-Infective Agents; D064704:Levofloxacin
bacterial replication; pharmacokinetics-pharmacodynamics; therapy duration